Determination of Expiry Date in Pharma Oral Dosage Forms: Stability, ICH Guidelines & Shelf-Life Calculation (2026 Guide)
1. What is Expiry Date / Shelf-Life?
Expiry Date: Date up to which product is expected to remain within approved specification when stored under labeled storage conditions.
Definition per ICH: Time during which drug product is expected to remain within specification if stored correctly.
For oral solids, expiry is generally 24 months. For oral liquids, 18-24 months. Based on data, not assumption. You cannot assign 36 months if you have only 12 months data, unless you have ICH Q1E extrapolation justification.
2. Regulatory Basis – ICH Guidelines You Must Know
| Guideline | Purpose |
|---|---|
| ICH Q1A(R2) | Stability Testing of New Drug Substances & Products – Mother guideline. Conditions, frequency. |
| ICH Q1B | Photostability testing |
| ICH Q1C | Stability for new dosage forms |
| ICH Q1D | Bracketing & Matrixing (reduced testing) |
| ICH Q1E | Evaluation of stability data – HOW to calculate shelf-life statistically |
| ICH Q1F | Stability for climatic zones III & IV (Hot/Humid – India) |
3. Types of Stability Studies for Expiry Determination
A. Long-Term (Real Time)
Condition: 25°C ±2°C / 60% ±5% RH (Zone II) or 30°C ±2°C / 65% ±5% RH (Zone IVA – India)
Duration: 12 months minimum at submission, continue to 24/36 months.
Use: This data ACTUALLY decides expiry. Most important.
B. Accelerated
Condition: 40°C ±2°C / 75% ±5% RH
Duration: 6 months.
Use: To predict effect of short-term excursions, early shelf-life. If significant change occurs at 6M accelerated, you need intermediate condition 30°C/65% RH.
C. Intermediate – 30°C/65% RH – 6 months – Only if significant change at accelerated.
D. Stress / Forced Degradation – For method validation – Heat, Acid, Base, Oxidation, Light. Not for expiry, but to identify degradation pathway.
E. In-use / Open Bottle – For oral liquids, bottles after opening – 30 days or 90 days in-use stability needed.
4. How Expiry Date is Actually Calculated – Step by Step
Step 1: Select Batches
Take 3 primary batches (pilot scale, min 1/10th commercial or 100,000 units whichever larger). Same formula, same container closure as commercial. For ANDA, 1 batch can be smaller.
Step 2: Put on Stability & Test Critical Parameters
For Oral Dosage, test these at each time point (0,3,6,9,12,18,24,36M for long-term; 0,3,6M for accelerated):
- Physical: Appearance, Hardness (tablet), Disintegration, Moisture (LOD / KF), Average weight
- Chemical: Assay (must be 90.0% – 110.0% typically), Related Substances / Degradation products, Content Uniformity
- Performance: Dissolution (Most critical – Q point), For capsules: Dissolution + Disintegration
- Micro: For oral liquids – Preservative efficacy, Microbial limits
- Package: Functionality of closure
Step 3: Define Significant Change (ICH)
Significant change at accelerated means:
1. 5% loss in assay from initial (e.g., 99% → 94%)
2. Degradation product exceeding limit
3. Dissolution fails – 12 units fail Stage 2
4. pH, appearance fail
5. For some, hardness, disintegration change
If significant change occurs, you CANNOT extrapolate shelf-life. You must go to intermediate data.
Step 4: Apply ICH Q1E Statistical Evaluation
For quantifiable attributes (Assay, Degradation):
1. Plot assay vs time for 3 batches.
2. Check if batch-to-batch variation is significant (p < 0.25). If no, pool data.
3. Perform linear regression. Calculate 95% confidence interval (one-sided or two-sided).
4. Shelf-life = Time where 95% CI intersects acceptance criteria (e.g., 90% assay).
Simplified Rule for Most Companies: If 12M real-time data shows no significant change, and accelerated 6M shows no significant change, you can propose 2x real-time data but max 24M. E.g., 12M data → Propose 24M expiry. This is ICH Q1E extrapolation rule.
Example: Tablet batch: Initial assay 99.5%, 12M 98.8%, 18M 98.2% (all within 90-110%), dissolution 98% → 92% (Q=80% limit), impurity 0.2% → 0.4% (limit NMT 1.0%). No trend crossing limit before 24M. So 24M expiry granted.
5. Container Closure Matters
Expiry depends on pack. Same tablet:
- Alu-Alu Blister: Best moisture protection → 36 months possible
- Alu-PVC Blister: Moderate → 24 months
- HDPE Bottle with desiccant: Depends on opening simulation → 24 months
- Bulk pack 1000 tabs in drum: Only 6-12 months after opening
You must put stability in FINAL market pack. If you have multiple packs, use bracketing per ICH Q1D – test extremes (e.g., 30’s blister and 500’s bottle).
6. Special Cases for Oral Forms
| Dosage Form | Extra Tests | Typical Shelf-life |
|---|---|---|
| Tablets (coated/uncoated) | Hardness, Disintegration, Moisture, Dissolution | 24-36 Months |
| Hard Gel Capsules | Brittleness, Moisture, Micro (gelatin susceptible) | 24 Months |
| Soft Gel Capsules | Leak test, Pliability, Assay leak | 18-24 Months |
| Oral Solution / Syrup | pH, Preservative assay & efficacy, Crystal formation, Osmolality | 18-24 Months (In-use 30 days) |
| Dry Syrup (for reconstitution) | Reconstituted stability 7-10 days, Moisture, Resuspendability | 24 Months dry, 7 days after reconstitution |
7. Common Mistakes That Lead to FDA Query
- Using stability data from Alu-Alu but selling in Alu-PVC – Pack mismatch = Rejection
- Not performing dissolution profile comparison – Only single point Q = Insufficient for ANDA
- Assigning 36M expiry with only 12M data and significant change at accelerated – No extrapolation allowed
- Not including in-use study for multi-dose oral liquids
- Statistical evaluation missing – Only statement “product stable” without Q1E CI calculation
Conclusion
Expiry date is not a guess. It is a data-driven commitment that your tablet will give same dose on day 1 and day 730. Follow ICH Q1A for conditions, Q1D for reduced testing, Q1E for calculation. For India Zone IVb (30°C/75% RH), if you want global filing, always do both 25/60 and 30/75.
Golden Rule: Long-term decides shelf-life, accelerated supports it, statistical analysis proves it.
⚠️ Disclaimer
Educational guide based on ICH Q1A(R2), Q1E, FDA Stability Guidance. Not regulatory advice. Consult stability expert for filing. Data as of Aug 2026.
About the Author
Mahummed Asif is a experienced pharmaceutical Quality Assurance professional and publisher of Pharmashare. He has worked with leading Pharmaceutical organizations and has developed extensive expertise in Quality Assurance, deviation management, investigations, CAPA, QMS, Product Life Cycle Management, change control, risk management, validation, product complaints, product recalls, and regulatory compliance. He is passionate about sharing practical pharmaceutical knowledge with professionals, students, and quality practitioners across the industry.